Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Durect Corp.
DescriptionSustained release oral hydromorphone using Durect's Oradur sustained release technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat chronic pain
Regulatory Designation
PartnerPain Therapeutics Inc.;
Pfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today